ripekg:evaluation/RIPEA237F9DCBC31EFBBD |
prov:used |
ripekg:study-design-evidence/RIPEA237F9DCBC31EFBBD |
ripekg:study-design-evidence/RIPEA237F9DCBC31EFBBD |
rdf:type |
rdfs:Resource |
ripekg:study-design-evidence/RIPEA237F9DCBC31EFBBD |
rdf:type |
owl:Thing |
ripekg:study-design-evidence/RIPEA237F9DCBC31EFBBD |
rdf:type |
ripe:IntegrityAssessmentEvidenceIntegrity assessment evidence |
ripekg:study-design-evidence/RIPEA237F9DCBC31EFBBD |
rdf:type |
ripe:StudyDesignEvidenceStudy design evidence |
ripekg:study-design-evidence/RIPEA237F9DCBC31EFBBD |
rdf:type |
tido:Evidence |
ripekg:study-design-evidence/RIPEA237F9DCBC31EFBBD |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA237F9DCBC31EFBBD |
ripekg:study-design-evidence/RIPEA237F9DCBC31EFBBD |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA237F9DCBC31EFBBD |
ripekg:study-design-evidence/RIPEA237F9DCBC31EFBBD |
ripe:concerns |
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial |
ripekg:study-design-evidence/RIPEA237F9DCBC31EFBBD |
ripe:recruitmentEndDate |
18-02-2019 |
ripekg:study-design-evidence/RIPEA237F9DCBC31EFBBD |
ripe:recruitmentEndDateExtractionRationale |
Setting: 'Six sites in China from 23 February 2016 to 18 February 2019.' |
ripekg:study-design-evidence/RIPEA237F9DCBC31EFBBD |
ripe:recruitmentStartDate |
23-02-2016 |
ripekg:study-design-evidence/RIPEA237F9DCBC31EFBBD |
ripe:recruitmentStartDateExtractionRationale |
Setting: 'Six sites in China from 23 February 2016 to 18 February 2019. ' |
ripekg:study-design-evidence/RIPEA237F9DCBC31EFBBD |
ripe:studyEndDateExtractionRationale |
No explicit study end date found. The last follow-up date was reported as March 1, 2024, but this is not the study end date. |
ripekg:study-design-evidence/RIPEA237F9DCBC31EFBBD |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA237F9DCBC31EFBBD-human-2-2 |
ripekg:study-design-evidence/RIPEA237F9DCBC31EFBBD |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA237F9DCBC31EFBBD-inspectai-2-2 |